Approximately 6,000 senior citizens' lives could be saved annually by a new vaccine.

The United States has made progress towards preventing tens of thousands of cases of respiratory syncytial virus (RSV).

Recent findings from the pharmaceutical company GSK demonstrate that its RSV vaccination

The findings are the first RSV vaccine findings to be supported and validated by the peer review process

According to research, just 7 out of 12,467 participants who received the vaccine's single dosage

"This is undoubtedly an important achievement," Dean L. Winslow, MD, professor of medicine

Moreover, RSV vaccinations are being created for high-risk newborns and expectant moms.